NCT05059145

A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis

Status unknown Phase 2 Last updated 20 May 2022

What this trial tests

Phase 2 trial testing Chlorhexidine Gluconate in Candidiasis, Vulvovaginal in 60 participants. Status unknown.

Timeline

27 April 2022

Primary endpoint
31 December 2024

31 December 2025

Quick facts

Lead sponsor	Karolinska Institutet
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	27 April 2022
Primary completion	31 December 2024
Estimated completion	31 December 2025
Sites	1 location across Sweden

Drugs / interventions tested

• Chlorhexidine Gluconate — full drug profile →
• Fluconazole (fluconazole) — full drug profile →

Conditions studied

• Candidiasis, Vulvovaginal — all drugs for Candidiasis, Vulvovaginal →

Sponsor

Karolinska Institutet

Who can join

Adults 18 to 50, female only, with Candidiasis, Vulvovaginal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall aim of this study is to investigate if vaginally applied 1% chlorhexidine gluconate (CHG) could be an alternative treatment to oral fluconazole (FLZ), both during an acute episode and as prophylaxis, against recurrent infections of vulvovaginal candidiasis (RVVC).

RVVC is very common in fertile women. Up to six months of treatment with FLZ is recommended for RVVC. Over the last ten years, the use of FLZ has increased markedly in many countries. No major problems have been noted with resistance development, but there is concern that this will occur in the future and alternative treatments are requested. In recent years, it has emerged that flukonazol interacts with several different types of drugs that are common in the patient group; several antidepressants, pain relief at dysmenorrhea (NSAID) and oral contraceptives to name a few.

In Sweden an over-the-counter vaginal cream consisting of 1% chlorhexidine gluconate (Hibitane®) is available with the indication antiseptic use in vaginal examinations, especially during childbirth. The product has been used for a long time in various gynecological and obstetric surgical procedures. Hibitane® is approved during pregnancy and the cream is usually well tolerated.

The research group has previously done an in vitro study in which we analyzed the effect of FLZ and CHG's ability to kill fungal cells and to break down existing biofilm or prevent new biofilm formation. The biofilm formation is an important stage for the fungal cells to attach to surfaces such as skin and mucosa and is considered a first step in the development of an infection. In the biofilm, the fungus can hide from the immune system and also to some extent for various treatments aimed against the fungus. The results of the study showed that CHG was better than FLZ both at killing the fungal cells and preventing new biofilm from forming and dissolving already established "old" biofilm. This effect is absolutely crucial for successful treatment with antimycotics. These encouraging results form the basis of the planned study.

If CHG is at least as effective as FLZ with little impact on vaginal lactobacillus, with high tolerability and without cytotoxic effect on epithelial cells, the results of the study might lead to major benefits to the patients with reduced risk of systemic side effects such as drug interactions, development of drug resistance and reduced drug costs.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Vaginal chlorhexidine gluconate versus fluconazole for recurrent vulvovaginal candidiasis: A randomized noninferiority trial.
   Alvendal C, Hasselrot T, Balduck M, Edfeldt G, et al · · 2026 · PMID 41557647 · DOI 10.1371/journal.pone.0340862